Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PRENW
Upturn stock ratingUpturn stock rating

Prenetics Holding Company Limited (PRENW)

Upturn stock ratingUpturn stock rating
$0.04
Last Close (24-hour delay)
Profit since last BUY0%
upturn advisory
Consider higher Upturn Star rating
BUY since 1 day
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: PRENW (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $0

1 Year Target Price $0

Analysts Price Target For last 52 week
$0Target price
Low$
Current$0.04
high$

Analysis of Past Performance

Type Stock
Historic Profit 0%
Avg. Invested days 1
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 5.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 0.17
52 Weeks Range 0.01 - 0.05
Updated Date 06/21/2025
52 Weeks Range 0.01 - 0.05
Updated Date 06/21/2025
Dividends yield (FY) -
Basic EPS (TTM) -11.04

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -115.91%
Operating Margin (TTM) -61.41%

Management Effectiveness

Return on Assets (TTM) -14.52%
Return on Equity (TTM) -28.48%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 9154745
Shares Outstanding -
Shares Floating 9154745
Percent Insiders -
Percent Institutions -

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Prenetics Holding Company Limited

stock logo

Company Overview

overview logo History and Background

Prenetics Holding Company Limited was founded in 2013. It has evolved from a DNA testing company to a global leader in genomic and diagnostic testing, focusing on early disease detection and personalized healthcare.

business area logo Core Business Areas

  • Genomic and Diagnostic Testing: Offers a range of DNA testing services, including cancer screening, disease risk assessment, and pharmacogenomics.
  • Prevention and Wellness: Provides personalized prevention and wellness solutions, including health screening programs and lifestyle recommendations.
  • Digital Health: Develops digital health platforms and applications to deliver personalized healthcare services and connect patients with healthcare providers.

leadership logo Leadership and Structure

Avanish Sahai serves as the Chief Executive Officer. The company operates with a board of directors overseeing strategic direction.

Top Products and Market Share

overview logo Key Offerings

  • CircleDNA: A consumer DNA test that provides insights into health risks, ancestry, and lifestyle traits. It is one of their key revenue drivers. Competitors include 23andMe and AncestryDNA. Market share is estimated around 5% in the overall consumer DNA testing market, however their core focus is in Asia, where they have a greater foothold.
  • ColoClear: A non-invasive stool DNA screening test for colorectal cancer detection. This is a fast growing part of their testing menu. Key competitors are Exact Sciences (EXAS) and Guardant Health (GH). Market share is still emerging but has strong upside potential.
  • iGenes: Cancer diagnostics focused on personalized treatment decision making.

Market Dynamics

industry overview logo Industry Overview

The genomic and diagnostic testing market is experiencing significant growth, driven by increasing awareness of personalized medicine, advancements in technology, and growing prevalence of chronic diseases.

Positioning

Prenetics is positioned as a leader in personalized healthcare, offering a comprehensive range of genomic and diagnostic testing services. Its competitive advantages include its strong technology platform, international presence, and focus on early disease detection.

Total Addressable Market (TAM)

The global molecular diagnostics market is expected to reach approximately $16 billion. Prenetics is well positioned to capture a portion of this TAM with its diversified product portfolio.

Upturn SWOT Analysis

Strengths

  • Strong technology platform
  • International presence
  • Focus on early disease detection
  • Diversified product portfolio

Weaknesses

  • Limited brand recognition compared to larger competitors
  • Requires regulatory approvals in various markets
  • Cash flow struggles due to acquisitions

Opportunities

  • Expanding into new markets
  • Developing new diagnostic tests
  • Partnering with healthcare providers
  • Leveraging the rising personalized medicine trend

Threats

  • Intense competition
  • Regulatory changes
  • Economic downturn
  • Data privacy concerns

Competitors and Market Share

competitor logo Key Competitors

  • EXAS
  • ILMN
  • TMO
  • DGX

Competitive Landscape

Prenetics faces stiff competition from established players with greater resources. Its strength lies in its niche products and market focuses.

Major Acquisitions

ACT Genomics

  • Year: 2022
  • Acquisition Price (USD millions): 200
  • Strategic Rationale: Expanded Prenetics' cancer genomics and diagnostics capabilities.

Growth Trajectory and Initiatives

Historical Growth: Prenetics has demonstrated growth through acquisitions and expansion of its testing portfolio.

Future Projections: Analyst estimates project future growth driven by demand for cancer screening, genomic testing, and precision medicine. However, these are speculative

Recent Initiatives: Recent initiatives include acquiring new companies that specialize in testing and forging partnerships with healthcare providers to expand reach.

Summary

Prenetics is operating in the rapidly growing molecular diagnostics space. The Company offers cancer and disease diagnostics testing for consumers. Their past aggressive acquisition strategy may be the cause of the recent cash flow challenges. The growth of this company will depend on successfully capturing market share away from entrenched competitors in a highly regulated market, and improving its financial performance to be cash flow positive.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings
  • Industry reports
  • Analyst estimates
  • Market research reports

Disclaimers:

The information provided is for informational purposes only and does not constitute investment advice. Market data and analyst estimates are subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Prenetics Holding Company Limited

Exchange NASDAQ
Headquaters -
IPO Launch date 2022-05-18
Co-Founder, Chairperson & CEO Mr. Sheng Wu Yeung
Sector Healthcare
Industry Diagnostics & Research
Full time employees 285
Full time employees 285

Prenetics Global Limited, a consumer health company, focuses on empowering individuals to take control of their health through science-backed solutions in Hong Kong, Taiwan, the United States, and internationally. The company operates in three segments: Prevention, Diagnostics, and Consumer Health. It operates IM8 Health that sells health and wellness products; and provides fulfillment and distribution services for sports nutrition products under the Consumer Health segment. The company is also involved in the operation of CircleDNA, a consumer genetic testing brand that uses next-generation sequencing (NGS) technology to provide comprehensive insights into health, wellness, and genetic predispositions under Prevention segment.; and ACT Genomics that provides precision oncology testing services under the Diagnostics segment. In addition, it develops and commercializes multi-cancer early detection technologies. Further, the company offers a range of genomic profiling panels tailored for requirements and clinician needs. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.